2.1.1. Stage 1: Preparatory Work Which Was Performed by the Government of Tanzania, as well as the Administrators and Clinicians from MNH

Over the last few years, there have been active efforts by Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania, to enhance the availability of appropriate treatment for hematologic disorders. This has been done through the development of a sickle cell programme as well as with training for doctors and nurses, by forming partnerships with centres performing HSCT in India. The details of this are as given in Table 1.

2.1.2. Stage 2: Exploratory Gap Analysis by the Teams from MNH and HCG-IHC

A joint team of MNH (Muhimbili National Hospital) and HCG-IHC conducted an initial site visit at MNH, Upanga, and Mloganzila campuses, in October 2021 to perform a gap analysis as per the Assessment Tool given in Table 2. The infrastructure and the biomedical equipments were divided between MNH, Mloganzila campus and MNH, Upanga campus, which were 30 kilometres and about 1 hour apart by road. The details of these are mentioned in Table 3.

2.1.3. Stage 3: Activities for Closure of Gaps

The activities for protocol transfer and adaptation, online training, hands-on training, and policymaking were divided between these two phases. Four teams were created for this purpose. Each team was headed by a member of HCG-IHC.

2.1.4. Stage 4: Stem Cell Transplantation Camps

As of now, two “HSCT Camps” have been conducted. The first camp was between 23^rd November and 17^th December, 2021, when 5 patients underwent autologous stem cell transplantation. The second camp was conducted between 20^th February and 10^th March 2022, when 6 patients underwent autologous stem cell transplantation.

The pretransplant workup and consenting were performed by the MNH team in Tanzania and were approved by the HCG-IHC team via videoconferencing. The conditioning regimen was prepared by the HCG-IHC team and was shared with the MNH team via e-mail. The scheduling of apheresis was done such that two patients could be apheresed per day. G-CSF for mobilization was thus started in a staggered manner by the MNH team. The HCG-IHC team of 4 members (program director, apheresis director, one transplant nurse and one attending physician) reached Tanzania one day before the first apheresis was due, along with the essential drugs and stem cell apheresis kits and consumables.

The stem cell harvest, CD34+ cell enumeration, conditioning chemotherapy, stem cell infusion, and the posttransplant clinical and nursing care were done jointly by the HGC-IHC and MNH teams.

2.2.1. Transplantation Details

Injection Filgrastim (5 mcg/kg twice daily for 4 days and 10 mcg/kg on the morning of the apheresis) was used for mobilization in all patients. However, due to an assumed difficulty in the pre-harvest enumeration of CD34+ cells in the peripheral blood as well as a limitation in the number of apheresis kits and consumables, injection of Plerixafor (24 mg) via subcutaneous route was given to all the patients to prevent harvest failures in the first camp. However, in the second HSCT camp, reliable preharvest CD34+ cell enumeration could be performed from the peripheral blood. Hence, plerixafor was required for only one patient.

Similarly, to ensure adequate venous access for apheresis, all the 5 patients in the first camp underwent insertion of a central venous catheter in the femoral vein. A double-lumen dialysis catheter was used for this. However, during the second camp, peripheral blood apheresis could be done successfully with peripheral venous access in all but one of the six patients.

Peripheral blood stem cells were harvested through apheresis performed with the Spectra Optia™ cell separator (TERUMOBCT™, Colorado, USA) via continuous mononuclear cell collection procedure as per the manufacturer’s instructions. A total of 4 total blood volumes (TBV) were processed for each patient over four-five hours with a target of getting a minimum dosage of 5 × 10⁶/kg CD34+ cells. All the patients tolerated the procedure for the full 4 TBVs without any adverse reactions and had an adequate stem cell dosage harvested in a single setting, except for one patient who required apheresis for two days.

The adequacy of the harvest was measured with CD34+ cell enumeration via flow cytometry and was cross-checked with the mononuclear cell count, which was performed by Leishman staining of the harvest smear. Gram staining and microbiologic culture of all the stem cell products were negative for microbiologic contamination.

Key challenges for the stem cell harvest and engraftment are noted in Table 5.

As mentioned earlier, up to the writing of this manuscript, two SCT camps have been conducted for 11 patients. The first camp involved autologous SCT for 5 patients with multiple myeloma, and the second one was conducted after 3 months for 5 myeloma and 1 patient with relapsed Hodgkin lymphoma. The stem cell products for the myeloma patients were stored at 2–6°C for the next 24–48 hours before infusion. For the Hodgkin lymphoma patient, stem cells were cryopreserved and stored in liquid nitrogen using the controlled rate freezer at −150°C. The peripheral blood stem cell harvest was done on the Upanga campus, and the patients and the stem cell products were transported to the SCT Unit was at MNH Mloganzila, which was 30 km away. This transport of patients and stem cells by road thus took about 1 hour. One test run of a noncryopreserved packed red cell unit and a cryopreserved buffy coat, each was conducted to validate the temperature control during transport.

None of the patients had any adverse transfusion reactions during the stem cell infusions.

The clinical details of the patients are given in Table 6. Overall, 10 patients with multiple myeloma and 1 patient with relapsed classical Hodgkin lymphoma (CHL) underwent autologous SCT. 3 patients (30%) had relapsed multiple myeloma. M : F ratio was 3 : 5, the median age was 43.6 years with a range of 31–65 years. The international staging system and cytogenetic risk assessment were not available for the patients. Imaging studies done for the CHL patient revealed that the patient was in CR2. 8 patients were conditioned with high-dose melphalan (200 mg/m²), and 2 patients were conditioned with a melphalan dose of 140 mg/m², one due to age >60 years and the other due to a prior history of renal failure requiring dialysis. The Hodgkin lymphoma patient received conditioning regimen with BCNU, cytarabine, etoposide, and melphalan (BEAM regimen).

All patients underwent cryotherapy as part of standard prophylaxis for oral mucositis. No gut decontamination was performed, and no antibiotics were used prophylactically.

A total of 8 units of SDP were required for all the patients during their cytopenic period with an average requirement of 0.72 bag during the neutropenic phase. A total of 15 units of granulocyte transfusions were required for the management of febrile neutropenia with an average requirement of 1.36 units during the neutropenic phase.

Major post-transplant complications were bacteremia (2), culture-negative febrile neutropenia (7), and gastro-intestinal infection (3) (Figure 1).

The median duration of the hospital stay was 19 ± 6 days. The median neutrophil engraftment was on 8.8 ± 0.8 days, and median platelet engraftment was 9.6 ± 2.4 days. 1 patient suffered from salmonella enteritis and was treated with meropenem as per the sensitivity report. Another patient had shigella enteritis and was treated with 3^rd generation cephalosporin (Cefixime) and fluoroquinolone (Levofloxacin) as per the culture and sensitivity report.

The median observation period for survivors was 75.45 days post-transplant (126 days–33 days), and these patients were followed up for a median of 552 days. The progression-free rate was 100% over a median observation period of 75.45 days. The cumulative incidence of relapse was nil (0%) and transplant-related mortality (TRM)/non-transplant-related mortality (NRM) in the first 100 days for 5 patients was nil (0%).